TransMedics Reports Third Quarter 2026 Financial Results
PR Newswire•05/11/2026•16:02 ET
0
Key Highlights
- ➤Q3 revenue $203.0 million, up 41% year over year
- ➤Raises FY 2026 revenue guidance to $764-$774 million, including PAD Aviation
- ➤Q3 net income $17.1 million, or $0.46 per diluted share
- ➤FDA approves ENHANCE Heart Part B and DENOVO Lung IDE trials
- ➤Wins first European transplant logistics tender in Italy
Expert Statements
Waleed Hassanein, President and Chief Executive Officer of TransMedics
“The third quarter of 2026 was the strongest in TransMedics' history, with record revenue and record case volume. Importantly, we delivered these results despite typical third quarter seasonality and before any contribution from ENHANCE Part B or DENOVO.”
Waleed Hassanein, President and Chief Executive Officer of TransMedics
“We enter 2027 with strong momentum and a robust set of growth catalysts. ENHANCE Heart Part B and DENOVO Lung target large, untapped heart and lung segments, with two shots on goal in each through OCS and CHOPS. In Europe, we plan to launch OCS NOP in Italy, the Netherlands and Belgium, building on our first European transplant logistics win. And OCS Kidney remains on track for first-in-human clinical experience in the second half of 2027, our path into the largest transplant market. Our strategy is clear. Our execution is proven. Our conviction has never been stronger. We are building the global platform to transform organ transplantation, and we strongly believe our best years are still ahead.”
TransMedics Reports Third Quarter 2026 Financial Results PR Newswire
Strong Revenue Generation Drives Increase in Full-Year 2026 Guidance; Recent Progress Positions Company for Continued Growth with Several Near- and Mid-Term Catalysts
Get started
Create a free account to read the full story.